Emmaus Life Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Revenues, net (Tables)

Revenues, net (Tables)

3 Months Ended

Mar. 31, 2026

Revenue From Contract With Customer [Abstract]

Summary of revenues disaggregated by category

Revenues, net by category were as follows (in thousands):


	For the three months ended March 31,
	2026				2025
Endari® - US	$	1,376	70	%	$	2,055	86	%
Endari® - International		583	29	%		198	8	%
Other		23	1	%		153	6	%
Revenues, net		1,982	100	%		2,406	100	%

Revenue Allowance and Accrual Activities

The following table summarizes the revenue allowance and accrual activities for the three months ended March 31, 2026 and March 31, 2025 (in thousands):


	Trade Discounts, Allowances and Chargebacks			Government Rebates and Other Incentives			Returns			Total
Balance as of January 1, 2026	$	1,029		$	8,129		$	178		$	9,336
Provision related to sales in the current year		127			532			17			676
Adjustments related to prior period sales		—			—			—			—
Credits and payments made		(184	)		(373	)		—			(557	)
Balance as of March 31, 2026	$	972		$	8,288		$	195		$	9,455

Balance as of January 1, 2025	$	1,135		$	6,812		$	138		$	8,085
Provision related to sales in the current year		192			746			27			965
Adjustments related to prior period sales		4			17			—			21
Credits and payments made		(251	)		(529	)		(81	)		(861	)
Balance as of March 31, 2025	$	1,080		$	7,046		$	84		$	8,210

Summarizes revenues from each of our customers accounted for 10% or more of net revenues

The following table summarizes revenues attributable to each of the customers that accounted for 10% or more of our net revenues in any of the periods shown:


	Three Months Ended March 31,
	2026			2025
Customer A		13	%		20	%
Customer B		14	%		10	%
Customer C		16	%		30	%
Customer D		19	%		15	%
Customer E		26	%		1	%